One Unsettled Question Sits Under Pfizer Stock
For questions about this article or underlying research, email help@trefis.com.
At the November 13, 2026 close, Pfizer (PFE) stock yields 5.9% in dividends, and that payout may be much of the reason people hold it. Management has named the loss of patent protection on several drugs as a key pressure on 2027. Pfizer’s ability to keep paying that dividend out of its free cash flow through those patent losses is not settled yet.

Pfizer Hands Most Free Cash Flow To Shareholders
On its November 3, 2026 call, analysts asked about Pfizer’s cost savings and about 2027. The patent losses management named for 2027 included Ibrance and Xtandi in the U.S., and Eliquis in international markets from the end of 2026.
Over the twelve months to September 27, 2026, Pfizer paid $9.79 billion in dividends against $11.8 billion of free cash flow. Over that period, Pfizer paid out about 83% of its free cash flow as dividends. Two years earlier, Pfizer paid out more than its free cash flow, paying $9.45 billion in dividends on $8.23 billion of free cash flow over the twelve months to September 29, 2024.
What Has Pfizer Said About Its Dividend And Debt?
Management has said its priorities have not changed, and keeping the dividend and growing it over time is one of them, alongside reinvesting in the business. Leverage, management’s own measure of Pfizer’s debt, ended the third quarter at 2.6 times, slightly below the 2026 target of 2.7 times. Management expects leverage to stay around current levels, or go modestly higher, while the patent losses play out.
To offset those losses, management points to its newly launched and acquired drugs, which brought in $3.8 billion in the third quarter, up 32% on an operational basis. Management also says Pfizer is on track to deliver nearly all of $7.2 billion of net cost savings by the end of 2026.
Pfizer Gives Its 2027 Outlook In December
Management plans to give Pfizer’s 2027 guidance in December 2026, as it did a year earlier. That will be the company’s first full forecast for 2027, the year management expects the Ibrance, Xtandi and Eliquis patent losses to weigh on sales.
Pfizer’s free cash flow for 2026, set against what it paid in dividends, is the figure to watch when it reports its fourth quarter, expected in February 2027. That 2026 figure comes mostly before the patent losses management expects in 2027.
Does This Mean You Should Act On PFE?
Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.
There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.
Spot an error or want more like this? Tell us in 10 seconds.